CENFRA, NATALIA
 Distribuzione geografica
Continente #
NA - Nord America 548
EU - Europa 334
AS - Asia 83
AF - Africa 7
SA - Sud America 3
Totale 975
Nazione #
US - Stati Uniti d'America 545
IT - Italia 200
SE - Svezia 59
SG - Singapore 28
IN - India 27
DE - Germania 19
CN - Cina 18
FI - Finlandia 16
BG - Bulgaria 11
UA - Ucraina 7
BE - Belgio 5
GB - Regno Unito 5
TG - Togo 5
CA - Canada 3
IR - Iran 3
EC - Ecuador 2
IE - Irlanda 2
JP - Giappone 2
NL - Olanda 2
PL - Polonia 2
PT - Portogallo 2
RO - Romania 2
AR - Argentina 1
EG - Egitto 1
ES - Italia 1
FR - Francia 1
PK - Pakistan 1
QA - Qatar 1
SC - Seychelles 1
TH - Thailandia 1
TR - Turchia 1
TW - Taiwan 1
Totale 975
Città #
Fairfield 87
Rome 65
Ashburn 49
Cambridge 37
Chandler 35
Seattle 35
Woodbridge 34
Wilmington 31
Houston 29
Singapore 19
Milan 17
Princeton 17
San Paolo di Civitate 12
Ann Arbor 11
Beijing 11
Boston 11
Sofia 11
Plano 10
Des Moines 9
Lawrence 9
Helsinki 8
San Diego 8
Andover 7
Millbury 7
Brussels 5
Lomé 5
Bologna 4
Bolzano 4
Naples 4
Bremen 3
Dearborn 3
Fremont 3
Hefei 3
Jacksonville 3
New York 3
Simi Valley 3
Alcamo 2
Boardman 2
Bühl 2
Cogliate 2
Dublin 2
Eindhoven 2
Genoa 2
Genzano Di Roma 2
Guayaquil 2
Marostica 2
Monza 2
Pavia 2
Pescara 2
Salerno 2
San Donato di Lecce 2
Santa Clara 2
Southend 2
Tokyo 2
Toronto 2
Torun 2
Viseu 2
Al Mansurah 1
Austin 1
Bangkok 1
Barberino di Mugello 1
Barcelona 1
Bolzano Vicentino 1
Brentford 1
Buffalo 1
Chennai 1
Doha 1
Faisalabad 1
Falls Church 1
Federal 1
Frankfurt am Main 1
Indiana 1
Jinan 1
Laurel 1
Legnano 1
London 1
Los Angeles 1
Magenta 1
Mahé 1
Nanchang 1
Norwalk 1
Nürnberg 1
Ottawa 1
Phoenix 1
Prescot 1
Provo 1
Pune 1
Redwood City 1
San Mateo 1
Seminole 1
Stanford 1
Trumbull 1
Totale 689
Nome #
An uncommon clinical presentation of primary pancreatic lymphoma. Bleeding. Case report and literature review 99
Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine 85
Genetic lesions disrupting calreticulin 3′-untranslated region in JAK2 mutation-negative polycythemia vera 84
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 80
Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease 79
HDAC inhibition by valproic acid decreases JAK2V617F levels in myeloproliferative neoplasms via up-regulation of miR-101, in vivo and in vitro 78
Comparison of 18F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkin's lymphoma 67
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene 66
A complete remission induced by valproic acid in a patient with essential thrombocytemia JAKV617F- positive 65
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 63
A novel germline mutation in the 3'Untranslated region of Calreticulin gene induces JAK/STAT signaling activation and Erythrocytosis. 56
A novel germline CALR mutation affecting an evolutionary conserved region of 3’UTR in JAK2-negative siblings with Polycythemia Vera 54
null 46
AN ANALYSIS ON THE ROLE OF FDG PET IN HODGKIN LYMPHOMA STAGING 33
QUANTIFICATION OF JAK2WT AND JAK2V617F ALLELE IN mRNA FROM PH(-) MYELOPROLIFERATIVE NEOPLASMS PATIENTS: CORRELATION WITH DNA ALLELE BURDEN AND DESEASE PROGRESSION 24
IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study 16
‘Real Life’ experience in a ‘difficult to treat’ patient population of non-Hodgkin lymphomas using the R-COMP regimen 15
Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation 9
LEUKOCYTOSIS IN LOW-INTERMEDIATE RISK ACUTE PROMYELOCYTIC LEUKEMIA DURING ATRA-ATO INDUCTION THERAPY: A REAL-LIFE STUDY 7
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications 1
Totale 1.027
Categoria #
all - tutte 3.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.406


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020141 0 0 0 9 18 18 26 22 19 12 9 8
2020/202193 2 11 0 3 4 3 2 13 19 27 4 5
2021/2022183 10 13 9 7 16 20 3 18 16 13 23 35
2022/2023209 32 38 13 15 13 21 8 31 22 3 6 7
2023/2024193 10 16 9 16 22 33 7 14 4 22 26 14
2024/202562 18 10 19 15 0 0 0 0 0 0 0 0
Totale 1.027